Novo Nordisk A/S (NVO) Q1 2024 Earnings Conference Call May 2, 2024 7:00 AM ET Company Participants Lars Fruergaard Jørgensen - Chief Executive Officer Camilla Sylvest - Executive Vice President, Head of Commercial Strategy & Corporate Affairs Doug Langa - Executive Vice President, Head of North America Operations Martin Holst Lange - Executive Vice President, Head of Development Karsten Munk Knudsen - Chief Financial Officer Daniel Bohsen - Head of Investor Relations Conference Call Participants Michae ...

Core Insights - Novo Nordisk A/S reported first-quarter 2024 earnings of 83 cents per ADR, exceeding the Zacks Consensus Estimate of 77 cents, and up from 63 cents per ADR in the same quarter last year [1] - Revenues reached $9.52 billion, a 22% increase in Danish kroner and a 24% increase at constant exchange rates, surpassing the Zacks Consensus Estimate of $9.23 billion [1] - The growth in revenues was primarily driven by increased sales in the Diabetes and Obesity Care segments, particularly from GLP-1 products, despite declines in insulin and Rare disease sales [1] Financial Performance - The Diabetes and Obesity Care segment reported sales of DKK 61 billion, reflecting a growth of 27% [4] - Sales of Ozempic reached DKK 27.8 billion, up 43%, while Rybelsus sales increased by 17% to DKK 5 billion [4] - Obesity Care sales, including Saxenda and Wegovy, rose 42% to DKK 11 billion, with Wegovy sales surging 107% to DKK 9.4 billion [5] - Rare disease segment sales decreased by 3% to DKK 4.4 billion, with specific declines in rare blood disorder products and hemophilia A products [5] Cost Analysis - Sales and distribution costs increased by 7% in DKK and 8% at constant exchange rates to DKK 13.3 billion, attributed to promotional activities for Wegovy and Rybelsus [5] - Research and development costs rose by 28% to DKK 8.6 billion, driven by increased clinical activity and research efforts [6] - Administrative costs increased by 8% in DKK to DKK 1.2 billion [6] Future Outlook - Novo Nordisk updated its sales growth expectation to a range of 19-27%, up from the previous guidance of 18-26% [7] - Operating profit is now expected to grow between 22-30%, compared to the prior guidance of 21-29% [7] - The updated guidance reflects steady growth in North America and International Operations, primarily driven by GLP-1-based products [7] - The company is addressing supply constraints and drug shortages by ramping up production capacity for GLP-1 products [8]

ToplineDanish pharma giant Novo Nordisk raised its 2024 outlook and beat first-quarter profit expectations in its first-quarter earnings report Thursday morning, amid a frenzied rush to match booming consumer demand for its popular weight loss and diabetes drugs Ozempic and Wegovy.Wegovy is an injectable weight loss medicine that has helped Novo Nordisk profits soar. UCG/Universal Images Group via Getty Images Key FactsNovo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first t ...

This morning, pharmaceuticals company Novo Nordisk reported triumphant Q1 2024 financial results before markets opened.Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.One of the more memorable highlights was certainly the fact that Novo Nordisk’s sales increased by 22% in Danish kroner (by 24% at constant exchange rates) to DKK 65.3 billion for the period.  Profits up by over a quarterCopy link to sectionMeanwhile, operating profit increased by 27% in ...

The injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April 24, 2024 in Chicago, Illinois.Danish pharmaceutical giant Novo Nordisk, which became the most valuable company in Europe last year due to the blockbuster success of its weight loss drugs, on Thursday beat profit estimates for the first quarter.Net profit rose 28% year-on-year to 25.4 billion Danish kroner ($3.65 billion), versus analyst expectations of 23.7 billion kroner, according to LSEG data.Sales of popular ...

The Federal Trade Commission on Tuesday said it is challenging hundreds of alleged "junk" patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk's blockbuster diabetes drugs Ozempic, Saxenda and Victoza.The announcement expands the Biden administration's effort to crack down on alleged patent abuses by the pharmaceutical industry. The FTC has argued that drugmakers are needlessly listing dozens of extra patents for branded medications to keep their drug prices high and stal ...

Danish pharma goliath, Novo Nordisk (NVO) , is slated to report first-quarter 2024 results on May 2, before the opening bell.The Zacks Consensus Estimate for the company’s first-quarter revenues is pegged at $9.23 billion, while the same for earnings is pinned at 77 cents per share, both indicating significant increases from the year-ago quarter.Revenue growth in the first quarter of 2024 is expected to have been driven by strong demand for Novo Nordisk’s diabetes and obesity care medicines, especially sema ...

aprott Novo Nordisk A/S (NVO) secured the FDA approval for Wegovy, the weight loss version of the compound called semaglutide, for the indication of reducing risks of major cardiovascular adverse events ('MACE') in early March. Novo Nordisk is already enjoying significant commercial success with the type 2 diabetes version of semaglutide called Ozempic, and more recently, Wegovy is off to a strong start and would have higher uptake if it were not for the supply constraints as demand is exceeding supply. The ...

In the latest trading session, Novo Nordisk (NVO) closed at $126.16, marking a -1.93% move from the previous day. This change lagged the S&P 500's daily gain of 0.02%. On the other hand, the Dow registered a loss of 0.11%, and the technology-centric Nasdaq increased by 0.1%.The drugmaker's stock has dropped by 0.6% in the past month, exceeding the Medical sector's loss of 4.52% and the S&P 500's loss of 3.01%.Investors will be eagerly watching for the performance of Novo Nordisk in its upcoming earnings dis ...

The U.S. Senate has launched an investigation into the high price of Novo Nordisk's popular weight loss and diabetes drugs Ozempic and Wegovy in the United States, versus other countries where the drugs are sold.The investigation into the Danish drugmaker was announced by Sen. Bernie Sanders, the Vermont Independent who chairs the Health, Education, Labor and Pensions (HELP) Committee."The scientists at Novo Nordisk deserve great credit for developing these drugs that have the potential to be a game changer ...